PDF Cover

Sickle Cell Anemia Testing And Screening Market

Sickle Cell Anemia Testing And Screening Market

The market for Sickle Cell Anemia Testing And Screening was estimated at $462 million in 2024; it is anticipated to increase to $946 million by 2030, with projections indicating growth to around $1.72 billion by 2035.

Report ID:DS1801487
Author:Debadatta Patel - Senior Consultant
Published Date:July 2025
Datatree
Life Science
Medical Device
Sickle Cell Anemia Testing And Screening
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Sickle Cell Anemia Testing And Screening Market Outlook

Revenue, 2024

$462M

Forecast, 2034

$1.53B

CAGR, 2024 - 2034

12.7%
The Sickle Cell Anemia Testing And Screening industry revenue is expected to be around $520.4 million in 2025 and expected to showcase growth with 12.7% CAGR between 2025 and 2034. The significant expansion of the market for testing and screening for Sickle Cell Anemia can be linked to important factors. The rising occurrence of Sickle Cell Anemia globally and the improved recognition well as progress in diagnostic methods have greatly increased the need, for thorough testing and screening. Moreover government efforts that advocate identification and management of this inherited condition have additionally enhanced the importance and impact of the market.

Testing and screening for sickle cell anemia mainly focus on identifying hemoglobin levels in the blood - a significant marker of this condition that is commonly used in prenatal and newborn screenings as well as in diagnosing individuals showing symptoms of sickle cell anemia disorder. There has been an increase in the adoption of non invasive testing techniques and the incorporation of AI, into diagnostic processes.

Sickle Cell Anemia Testing And Screening market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Sickle Cell Anemia Testing And Screening market is projected to grow from $461.7 million in 2024 to $1.53 billion in 2034. This represents a CAGR of 12.7%, reflecting rising demand across Prenatal Diagnosis, Carrier Testing and Newborn Screening.
  • Abbott Laboratories, Bio-Rad Laboratories Inc., Biokit S.A. are among the leading players in this market, shaping its competitive landscape.
  • U.S. and Nigeria are the top markets within the Sickle Cell Anemia Testing And Screening market and are expected to observe the growth CAGR of 11.4% to 15.2% between 2024 and 2030.
  • Emerging markets including Indonesia, Ghana and Cameroon are expected to observe highest growth with CAGR ranging between 8.9% to 13.3%.
  • Transition like Technological Advancements is expected to add $145.1 million to the Sickle Cell Anemia Testing And Screening market growth by 2030
  • The Sickle Cell Anemia Testing And Screening market is set to add $1.1 billion between 2024 and 2034, with manufacturer targeting Carrier & Newborn Clinical Applications projected to gain a larger market share.
  • With Increasing global prevalence of sickle cell anemia, and Technological advancements in diagnostic procedures, Sickle Cell Anemia Testing And Screening market to expand 231% between 2024 and 2034.
sickle cell anemia testing and screening market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Sickle Cell Anemia Testing And Screening

Collaborations between firms and research organizations are also driving the advancement of new testing and screening techniques, for sickle cell anemia hastening research progress and aiding in bringing innovative diagnostic tools to market.

Growth Opportunities in North America and Africa

North America Outlook

North America, led by the United States, is a prominent region for Sickle Cell Anemia Testing and Screening. The regions growth is driven by advanced healthcare infrastructure, high awareness levels about the disease, and robust government initiatives promoting early detection. The presence of key players in the region, such as Bio-Rad Laboratories and Quest Diagnostics, intensifies the competition. However, it also opens up opportunities for strategic collaborations and technological advancements in Sickle Cell Anemia Testing and Screening. The increasing prevalence of Sickle Cell Anemia, particularly among the African American population, further drives the demand for efficient testing and screening solutions in the region.

Africa Outlook

Africa, particularly Sub-Saharan Africa, is a critical region for Sickle Cell Anemia Testing and Screening due to the high incidence of the disease. The region presents significant opportunities owing to the rising awareness campaigns about Sickle Cell Anemia and increasing government initiatives for newborn screening. Despite the challenges posed by limited healthcare infrastructure and funding, international aid and partnerships are driving advancements in testing and screening technologies. The competitive landscape is marked by the presence of both local and international players, with a focus on affordable and accessible solutions. Increased funding for research and development in Sickle Cell Anemia Testing and Screening is a key driver in this region.

Market Dynamics and Supply Chain

01

Driver: Increasing Global Prevalence of Sickle Cell Anemia, and Government Initiatives and Funding

The increasing occurrence of sickle cell anemia cases on a scale holds considerable importance for the testing and screening sector. Because the illness is also inherited in nature detecting it through testing and screening plays a vital role in effectively managing the condition leading to a rise in the demand for such services. The emphasis on healthcare and genetic counseling also strengthens the necessity, for sickle cell anemia testing and screening. Governments worldwide are also taking initiatives to increase awareness about sickle cell anemia. They are also also providing funding for research and development activities in this field. These initiatives are also expected to promote the growth of the sickle cell anemia testing and screening market.
The progress of methods, like the implementation of high performance liquid chromatography and genetic testing has also transformed the field of sickle cell anemia testing and screening in a significant way by providing increased precision and faster outcomes which ultimately improve patient care and results.
02

Restraint: High Cost of Testing

The significant cost linked to testing and screening for Sickle Cell Anemia is a factor in the market scene. Cutting edge technologies employed in these examinations like testing and hemoglobin electrophoresis tend to be pricey which could hinder access for numerous patients especially in less developed regions. This issue directly affects the demand, in the market since the expensive nature of these tests may discourage individuals from pursuing screening and testing services.
03

Opportunity: Evolving Consumer Needs and Technological Innovations

The rising awareness surrounding sickle cell anemia has led to a need for prompt and precise diagnosis methods to be available in the market soon enough to cater to this changing consumer demand, for better testing techniques that can detect the condition early on.
Advanced diagnostic technologies have opened up possibilities in the field of sickle cell anemia testing and screening by improving the precision and efficiency of detection through methods, like genetic testing and high performance liquid chromatography.
04

Challenge: Lack of Awareness

Despite the prevalence of Sickle Cell Anemia, there is a considerable lack of awareness about the disease and the importance of early testing and screening. This is particularly true in rural and underprivileged communities where access to information and healthcare services is limited. This lack of awareness and understanding about the disease and its potential complications can significantly impede market growth, as it reduces the perceived need for testing and screening services.

Supply Chain Landscape

1
Raw Material Procurement

Thermo Fisher Scientific

Merck KGaA

2
Testing Equipment Production

Bio-Rad Laboratories

PerkinElmer Inc

3
Distribution & Supply

McKesson Corporation

Cardinal Health

4
End User

Diagnostic Laboratories

Hospitals

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Sickle Cell Anemia Testing And Screening in Prenatal Diagnosis, Carrier & Newborn

Prenatal Diagnosis

Sickle Cell Anemia Testing and Screening is crucial in prenatal diagnosis. This application involves the use of advanced genetic testing technologies to identify the disease in the fetus. The most common method used is amniocentesis, where a small sample of the amniotic fluid is tested for the presence of the sickle cell gene. This early detection allows for proper medical planning and care. Top players in this field include Genzyme Corporation and PerkinElmer, known for their innovative and reliable testing solutions.

Newborn Screening

Newborn screening is another significant application of Sickle Cell Anemia Testing and Screening. In this application, a small blood sample from the newborns heel is tested for the disease. This is usually done using a technique known as High-Performance Liquid Chromatography.Early detection in newborns allows for immediate treatment, thus preventing severe complications. Bio-Rad Laboratories and Thermo Fisher Scientific are leading players in this sector, offering robust and accurate testing kits.

Carrier Testing

Carrier testing is a critical application in Sickle Cell Anemia Testing and Screening. It involves testing individuals, especially those of reproductive age, to determine if they carry the sickle cell trait. This is typically done using hemoglobin electrophoresis. Carrier testing is crucial in genetic counseling, helping potential parents understand the risks of passing the disease to their children.

Recent Developments

December 2024

Global diagnostics leader, Roche Diagnostics, launched a new high-throughput screening system for Sickle Cell Anemia, aiming to revolutionize early detection and management of the disease

October 2024

Genomic Health Inc. introduced a novel genetic test for Sickle Cell Anemia, leveraging advanced genomic sequencing technologies to provide more accurate and comprehensive results

August 2024

Thermo Fisher Scientific announced the development of a cutting-edge mass spectrometry-based test for Sickle Cell Anemia, offering a faster and more precise diagnostic solution.

The global market for Sickle Cell Anemia Testing and Screening has seen significant advancements in recent years. The emergence of innovative technologies and applications has revolutionized the industry, paving the way for more accurate, efficient, and accessible diagnostic solutions. One of the key trends driving this market is the increasing prevalence of Sickle Cell Anemia worldwide.

Impact of Industry Transitions on the Sickle Cell Anemia Testing And Screening Market

As a core segment of the Medical Device industry, the Sickle Cell Anemia Testing And Screening market develops in line with broader industry shifts. Over recent years, transitions such as Technological Advancements and Increased Awareness and Accessibility have redefined priorities across the Medical Device sector, influencing how the Sickle Cell Anemia Testing And Screening market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Technological Advancements

The Sickle Cell Anemia Testing and Screening industry has witnessed significant technological advancements in recent years. These advancements have facilitated the development of more accurate, efficient, and cost-effective testing methods. For instance, the introduction of High-Performance Liquid Chromatography and Isoelectric Focusing has revolutionized the industry, delivering quicker and more precise results. These technologies have not only improved the testing and screening process but also greatly influenced the healthcare industry by enabling early detection and better management of the disease. This industry transition is expected to add $145.1 million in the industry revenue between 2024 and 2030.
02

Increased Awareness and Accessibility

The growing awareness about Sickle Cell Anemia and the importance of early detection has led to increased demand for testing and screening services. Governments and health organizations worldwide are investing in awareness campaigns and making testing services more accessible to the public. This transition has not only impacted the Sickle Cell Anemia Testing and Screening industry by driving growth but also had a profound effect on public health policies and practices.
Report Price: $4,200

Related Reports

Loading related reports...